Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

Trial Details

NCT ID

NCT07014410

Phase

PHASE2

Sponsor

Zhejiang Cancer Hospital

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• pyrotinib dalpiciclib letrozole

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• The subjects voluntarily joined the study, signed the informed consent, and had good compliance
• Postmenopausal or premenopausal/perimenopausal women aged ≥18 years and ≤75 years
• Patients with recurrent/metastatic breast cancer confirmed by histopathology with positive ER expression and positive HER2 expression
• Have at least one extracranial measurable lesion that meets RECIST 1.1 criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.